Stefan Stortecky1, Anna Franzone1, Dik Heg2, David Tueller3, Stephane Noble4, Thomas Pilgrim1, Raban Jeger5, Stefan Toggweiler6, Enrico Ferrari7, Fabian Nietlispach8, Maurizio Taramasso8, Francesco Maisano8, Jürg Grünenfelder9, Olivier Muller10, Christoph Huber4, Marco Roffi4, Thierry Carrel1, Peter Wenaweser9, Stephan Windecker1. 1. Department of Cardiology and Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 2. Department of Clinical Research, Clinical Trials Unit and Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 3. Department of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland. 4. Division of Cardiology and Cardiovascular Surgery, University Hospital Geneva, Geneva, Switzerland. 5. Department of Cardiology, Basel University Hospital, University of Basel, Basel, Switzerland. 6. Department of Cardiology, Cantonal Hospital Lucerne, Lucerne, Switzerland. 7. Department of Cardiovascular Surgery, Cardiocentro Ticino, Lugano, Switzerland. 8. Department of Cardiology and Department of Cardiovascular Surgery, University Heart Centre Zurich, University Hospital Zurich, Zurich, Switzerland. 9. Department of Cardiology and Cardiovascular Surgery, Heart Clinic Hirslanden, Hirslanden Clinic Zurich, Zurich, Switzerland. 10. Department of Cardiology, Lausanne University Hospital-CHUV, Lausanne, Switzerland.
Abstract
AIMS: To describe temporal trends in adoption and performance of transcatheter aortic valve implantation (TAVI) in Switzerland over a period of 5 years. METHODS AND RESULTS: Between 2011 and 2015, a total of 3493 patients were consecutively included in the SwissTAVI Registry (NCT01368250) and analysed for the purpose of this study. The primary outcome measure was all-cause mortality at 1 year after TAVI. Over the 5-year period, a six-fold increase in the number of procedures was observed, whereas the baseline surgical risk estimated by the Society of Thoracic Surgeon (STS) score declined (from 6.8 ± 4.4% to 4.6 ± 3.6, P < 0.001). Overall, 1-year mortality amounted to 12.8%; mortality was highest in the first annual cohorts (14.6%, 14.8%, and 15.9% in 2011, 2012, and 2013, respectively) and decreased to 13.4% in 2014 and 9.7% in 2015. While rates of cerebrovascular events, peri-procedural myocardial infarction, moderate/severe paravalvular regurgitation, and Stage 3 acute kidney injury did not significantly change over time, a significant reduction in life threatening or major bleeding was noted at 30-day follow-up during the latest compared with earlier years of recruitment. CONCLUSION: This long-term recruitment analysis of a national TAVI registry showed rapid adoption paralleled by a progressive decrease of patients' baseline risk profile. Early and late survival significantly improved over time as did the rate of life threatening or major bleeding. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To describe temporal trends in adoption and performance of transcatheter aortic valve implantation (TAVI) in Switzerland over a period of 5 years. METHODS AND RESULTS: Between 2011 and 2015, a total of 3493 patients were consecutively included in the SwissTAVI Registry (NCT01368250) and analysed for the purpose of this study. The primary outcome measure was all-cause mortality at 1 year after TAVI. Over the 5-year period, a six-fold increase in the number of procedures was observed, whereas the baseline surgical risk estimated by the Society of Thoracic Surgeon (STS) score declined (from 6.8 ± 4.4% to 4.6 ± 3.6, P < 0.001). Overall, 1-year mortality amounted to 12.8%; mortality was highest in the first annual cohorts (14.6%, 14.8%, and 15.9% in 2011, 2012, and 2013, respectively) and decreased to 13.4% in 2014 and 9.7% in 2015. While rates of cerebrovascular events, peri-procedural myocardial infarction, moderate/severe paravalvular regurgitation, and Stage 3 acute kidney injury did not significantly change over time, a significant reduction in life threatening or major bleeding was noted at 30-day follow-up during the latest compared with earlier years of recruitment. CONCLUSION: This long-term recruitment analysis of a national TAVI registry showed rapid adoption paralleled by a progressive decrease of patients' baseline risk profile. Early and late survival significantly improved over time as did the rate of life threatening or major bleeding. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Taishi Okuno; Dik Heg; Jonas Lanz; Stefan Stortecky; Fabien Praz; Stephan Windecker; Thomas Pilgrim Journal: Int J Cardiol Heart Vasc Date: 2021-04-01
Authors: Ana Paula Tagliari; Enrico Ferrari; Philipp K Haager; Martin Oliver Schmiady; Luca Vicentini; Mara Gavazzoni; Marco Gennari; Lucas Jörg; Ahmed Aziz Khattab; Stefan Blöchlinger; Francesco Maisano; Maurizio Taramasso Journal: J Clin Med Date: 2020-12-20 Impact factor: 4.241
Authors: Taishi Okuno; Pavel Overtchouk; Masahiko Asami; Daijiro Tomii; Stefan Stortecky; Fabien Praz; Jonas Lanz; George C M Siontis; Christoph Gräni; Stephan Windecker; Thomas Pilgrim Journal: Sci Rep Date: 2021-09-21 Impact factor: 4.379
Authors: Lenka Kratochvílová; Petr Mašek; Marek Neuberg; Markéta Nováčková; Petr Toušek; Jakub Sulženko; Tomáš Buděšínský; And Viktor Kočka Journal: Eur Heart J Suppl Date: 2022-03-30 Impact factor: 1.624
Authors: Daniel Malebranche; Maximilian K M Hoffner; Adrian T Huber; Aleksandar Cicovic; Giancarlo Spano; Benedikt Bernhard; Joanna Bartkowiak; Taishi Okuno; Jonas Lanz; Lorenz Räber; Fabien Praz; Stefan Stortecky; Stephan Windecker; Thomas Pilgrim; Christoph Gräni Journal: BMC Cardiovasc Disord Date: 2022-04-18 Impact factor: 2.174
Authors: Victor Mauri; Mohamed Abdel-Wahab; Sabine Bleiziffer; Verena Veulemans; Alexander Sedaghat; Matti Adam; Georg Nickenig; Malte Kelm; Holger Thiele; Stephan Baldus; Tanja K Rudolph Journal: Clin Res Cardiol Date: 2021-11-09 Impact factor: 6.138
Authors: Anthony A Bavry; Taishi Okuno; Seyed Hossein Aalaei-Andabili; Dharam J Kumbhani; Stefan Stortecky; Masahiko Asami; Jonas Lanz; Stephan Windecker; Thomas Pilgrim Journal: Clin Cardiol Date: 2020-09-22 Impact factor: 2.882